Julie Kanter

Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy

Haploidentical Bone Marrow Transplantation for Sickle Cell Disease

National Alliance of Sickle Cell Centers Consensus Recommendations on Sickle Cell Disease Health Maintenance

Barriers and Facilitators to Comprehensive Pediatric Sickle Cell Care: A Qualitative Study

Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry

The clinical spectrum of <scp>HbSC</scp> sickle cell disease‐not a benign condition

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Iron restriction in sickle cell disease: When less is more

Current Methods of Newborn Screening Follow-Up for Sickle Cell Disease Are Highly Variable and without Quality Assurance: Results from the ENHANCE Study

Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial

An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel

Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell Disease

Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study

Real‐world implementation of the David–Carroll buprenorphine protocol for pain management in sickle cell disease

Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks

DISPLACE study shows poor quality of transcranial doppler ultrasound for stroke risk screening in sickle cell anemia

Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease

Challenges of Engaging Primary Care Providers in Specialized Telementoring Education About Sickle Cell Disease for Sickle Cell Specialists: Results from the Sickle Cell Disease Training and Mentoring Program for Primary Care Providers (STAMP) Project ECHO

Patient‐reported pregnancy loss and maternal complications: Insights from the sickle cell disease implementation consortium

Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease

Biopsychosocial Factors Associated With Pain and Pain-Related Outcomes in Adults and Children With Sickle Cell Disease: A Multivariable Analysis of the GRNDaD Multicenter Registry

Primary Analysis of Spartan: A Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Patients with Sickle Cell Disease Related Priapism

Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507

Common data model for sickle cell disease surveillance: considerations and implications

Evaluating the Discriminatory Ability of the Sickle Cell Data Collection Program’s Administrative Claims Case Definition in Identifying Adults With Sickle Cell Disease: Validation Study

Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study

Assessing barriers and facilitators to transition in sickle cell disease care prior to implementation of a formalized program

Patient and Family Opioid Decision-Making for Pain Management in Sickle Cell Disease: A Qualitative Study

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)